<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on July 28, 2020</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT03127423</url>
  </required_header>
  <id_info>
    <org_study_id>2016-828</org_study_id>
    <nct_id>NCT03127423</nct_id>
  </id_info>
  <brief_title>Comparison Between One-stage Hybrid Ablation and Thoracoscopic Surgical Ablation for Intractable Atrial Fibrillation</brief_title>
  <official_title>Comparison Between One-stage Hybrid Ablation and Thoracoscopic Surgical Ablation for Intractable Atrial Fibrillation</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>China National Center for Cardiovascular Diseases</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>China National Center for Cardiovascular Diseases</source>
  <brief_summary>
    <textblock>
      Previous evidence indicated that the outcomes of both video-assisted thoracoscopic surgical
      ablation and percutaneous radiofrequency ablation therapy for persistent atrial fibrillation
      (AF) were unsatisfied. Recently, hybrid ablation therapy for AF had encouraging outcomes.
      However, there were no randomized, controlled clinical studies to prove the effectiveness of
      this new strategy. This study is aimed to compare the outcomes of hybrid ablation with
      video-assisted thoracoscopic surgical ablation for persistent AF with enlarged left atrium.
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      This study is aimed to compare the outcomes of hybrid ablation with video-assisted
      thoracoscopic surgical ablation for persistent AF with enlarged left atrium.
    </textblock>
  </detailed_description>
  <overall_status>Recruiting</overall_status>
  <start_date>December 2016</start_date>
  <completion_date type="Anticipated">March 2022</completion_date>
  <primary_completion_date type="Anticipated">December 2021</primary_completion_date>
  <phase>N/A</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>Single (Outcomes Assessor)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Survival rate without any recurrence of AF</measure>
    <time_frame>At 12-month after intervention</time_frame>
    <description>Without detections of AF (episodes longer than 30 seconds)</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Burden of AF</measure>
    <time_frame>At 12-month after intervention</time_frame>
    <description>Burden of AF according to Tele-ECG-Card lasting for one week</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Quality of life score</measure>
    <time_frame>preoperative and 12-month after intervention</time_frame>
    <description>Measured with questionnaire of AF effect on Quality of Life</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Adverse events</measure>
    <time_frame>12 months follow up</time_frame>
    <description>Major adverse cardiovascular events; Major bleeding events; Major thromboembolic events.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Left atrial function</measure>
    <time_frame>preoperative and postoperative</time_frame>
    <description>left atrial ejection fraction and left atrial expansion index</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>postoperative complications</measure>
    <time_frame>30 days after operation</time_frame>
    <description>perioperative complication of catheter ablation and thoracoscopic surgical abaltion</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Survival rate without any recurrence of atrial tachyarrhythmia</measure>
    <time_frame>At 12-month after intervention</time_frame>
    <description>Survival rate without AF, atrial flutter or atrial tachycardia will be defined by absence of any of these electrocardiographically documented events lasting &gt; 30 seconds.</description>
  </secondary_outcome>
  <number_of_arms>2</number_of_arms>
  <enrollment type="Anticipated">100</enrollment>
  <condition>Persistent Atrial Fibrillation</condition>
  <arm_group>
    <arm_group_label>Hybrid ablation group</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Patients in this group will receive one-stop intervention with totally thoracoscopic surgical ablation and percutaneous catheter ablation.</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Thoracoscopic surgical ablation group</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
    <description>Patients in this group will receive only totally thoracoscopic surgical ablation with Fuwai lesion set.</description>
  </arm_group>
  <intervention>
    <intervention_type>Procedure</intervention_type>
    <intervention_name>Hybrid ablation</intervention_name>
    <description>This intervention includes totally thoracoscopic surgical ablation and percutaneous catheter ablation simultaneously.</description>
    <arm_group_label>Hybrid ablation group</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Procedure</intervention_type>
    <intervention_name>Thoracoscopic surgical ablation</intervention_name>
    <description>This intervention only includes totally thoracoscopic surgical ablation without percutaneous catheter ablation.</description>
    <arm_group_label>Thoracoscopic surgical ablation group</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  Patients with at least one anti-arrhythmic drugs

          -  Persistent AF lasting more than 1 year or with a left atrial diameter&gt;50mm

        Exclusion Criteria:

          -  Previous percutaneous catheter ablation or surgical ablation

          -  Presence of significant structural heart disease (dilated cardiomyopathy, hypertrophic
             cardiomyopathy, valvular heart disease, untreated coronary artery disease)

          -  Left atrial diameter&gt;60mm

          -  Previous thoracic or lung operation

          -  Left atrial thrombosis or left atrial appendage thrombosis

          -  Chronic obstructive pulmonary disease (COPD) (Forced expiratory volume in 1 second
             (FEV1)/Forced vital capacity (FVC)&lt;70%„ÄÅFEV1&lt;50% anticipated value)

          -  Bilateral carotid artery stenosis&gt;80%

          -  Refuse to participate in this study
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>N/A</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Zhe Zheng, MD,PhD</last_name>
    <role>Study Chair</role>
    <affiliation>Fuwai Hospital</affiliation>
  </overall_official>
  <overall_contact>
    <last_name>Zhe Zheng, MD,PhD</last_name>
    <phone>86-10-88396051</phone>
    <email>zhengzhe@fuwai.com</email>
  </overall_contact>
  <overall_contact_backup>
    <last_name>Haojie Li, MD</last_name>
    <phone>86-10-88322317</phone>
    <email>lihaojiefuwai@126.com</email>
  </overall_contact_backup>
  <location>
    <facility>
      <name>China National Center for Cardiovascular Diseases</name>
      <address>
        <city>Beijing</city>
        <state>Beijing</state>
        <zip>100037</zip>
        <country>China</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Zhe Zheng, M.D., Ph.D.</last_name>
      <phone>8610-8839-6051</phone>
      <email>zhengzhefuwai@tom.com</email>
    </contact>
    <investigator>
      <last_name>Zhe Zheng, M.D., Ph.D.</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location_countries>
    <country>China</country>
  </location_countries>
  <verification_date>May 2020</verification_date>
  <study_first_submitted>December 3, 2016</study_first_submitted>
  <study_first_submitted_qc>April 20, 2017</study_first_submitted_qc>
  <study_first_posted type="Actual">April 25, 2017</study_first_posted>
  <last_update_submitted>May 8, 2020</last_update_submitted>
  <last_update_submitted_qc>May 8, 2020</last_update_submitted_qc>
  <last_update_posted type="Actual">May 11, 2020</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <keyword>Hybrid ablation</keyword>
  <keyword>Thoracoscope</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Atrial Fibrillation</mesh_term>
  </condition_browse>
  <patient_data>
    <sharing_ipd>No</sharing_ipd>
  </patient_data>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

